Pavement

Abstract

The present invention relates to a patch (1) for the topical treatment of sinusitis in a person to be treated, the patch (1) comprising at least one active section (2) with at least one active ingredient and at least one adhesive section (3), wherein the patch (1) is designed to be at least partially, preferably completely, occlusive in the at least one active section (2) and / or in the at least one adhesive section (3), wherein it is provided according to the invention that the at least one active section (2) contains a therapeutically effective amount of a non-steroidal anti-inflammatory drug and / or its physiologically compatible compounds / salts and / or physiologically compatible chemical derivatives as the at least one active ingredient, and that the patch (1) has a shape that is adapted to the anatomical conditions of the application site, wherein the application site is in the face in the area of ​​at least one of the paranasal sinuses,preferably located in the area of ​​the cheek of the person to be treated, in order to enable targeted percutaneous treatment of the sinusitis.

Description

AREA OF INVENTION The present invention relates to a patch for the topical treatment of sinusitis in a patient, the patch comprising at least one active ingredient section and at least one adhesive section, wherein the patch is at least partially, preferably completely, occlusive in the at least one active ingredient section and / or in the at least one adhesive section. The patch can also be part of a kit. STATE OF THE ART Sinusitis, or inflammation of the sinuses, is a condition in which the mucous membranes of the sinuses are inflamed. The paranasal sinuses are cavities in the facial skeleton located beside, above, and behind the nose (maxillary sinuses, frontal sinuses, ethmoid sinuses, and sphenoid sinuses). The paranasal sinuses are connected to the nose via small openings. These openings allow for ventilation of the sinuses, and the fluid (secretions) produced within them can drain into the nose and throat. Like the nose, the paranasal sinuses are lined with mucous membrane. In sinusitis, these mucous membranes of the nose and paranasal sinuses become inflamed. Sinusitis is therefore also referred to as rhinosinusitis. The maxillary sinuses and ethmoid sinuses are most frequently affected, less often the frontal sinuses, and even less frequently the sphenoid sinuses. There are acute and chronic forms of sinusitis. This invention focuses on the treatment of acute sinusitis, but can also be used for supportive therapy.It is suitable for treating and curing chronic sinusitis. Sinusitis is usually treated locally with steam therapy or the administration of vasoconstrictors via nasal sprays. If a bacterial cause is suspected, antibiotics are administered systemically. Patches for pain management using an anti-inflammatory agent, for example from the group of non-steroidal anti-inflammatory drugs (NSAIDs), are already known in the art. However, these have a systemic effect and must be applied to the skin for an extended period of time. WO 2023 / 154479 A1 discloses, among other things, a patch for the treatment of sinusitis. Additionally, it discloses the use of an active ingredient from the NSAID group, for example diclofenac, as an oral adjunctive therapy in the systemic treatment of diseases using a patch disclosed therein. WO 20220531 28 A discloses a pharmaceutical composition comprising an active ingredient from the group of NSAIDs for the treatment of sinusitis. TASK OF INVENTION The object of the present invention is to provide a plaster for the treatment of sinusitis which makes it possible to transport the active ingredient quickly to the site of action in the face of the person to be treated and thus to shorten the application time as much as possible. PRESENTATION OF THE INVENTION The object of the invention is solved by a patch for the topical treatment of sinusitis according to claim 1. Claim 1 requires a sinusitis patch or a patch for the topical treatment of sinusitis in a person to be treated, the patch comprising at least one active section with at least one active ingredient and at least one adhesive section, wherein the patch is at least partially, preferably completely, occlusive in the at least one active section and / or in the at least one adhesive section, wherein it is provided according to the invention that the at least one active section contains a therapeutically effective amount of a non-steroidal anti-inflammatory drug and / or its physiologically compatible compounds / salts and / or physiologically compatible chemical derivatives as the at least one active ingredient, and that the patch has a shape that is adapted to the anatomical conditions of the application site.wherein the application site on the face is in the area of ​​at least one of the paranasal sinuses, preferably in the area of ​​a cheek, of the person to be treated, in order to enable targeted percutaneous treatment of sinusitis. The term "plaster" is well known to those skilled in the art. The general structure of a pharmaceutical plaster is also well known to those skilled in the art. The plaster comprises at least one active section to deposit the active ingredient within the plaster and deliver it to the person being treated, and at least one adhesive section to attach the plaster to the skin of the person being treated. The adhesive section and the active section can be arranged side by side in any configuration, or they can be congruent or overlapping, at least in part, thus forming a combined section. Preferably, however, the plaster has a border (of the active section) which is designed as an adhesive section or part thereof. Of course, it is possible that the plaster has further sections or layers. In particular, for example, a cover layer could be placed on the adhesive layer to prevent unwanted adhesion before treatment. Furthermore, for example, another layer could be placed on the side of the plaster facing away from the adhesive side, for instance to increase the occlusive effect. Alternatively, the patch can also have several active sections and / or several adhesive sections. However, it is particularly preferred that the active section and the adhesive section are at least partially congruent in the sense of being arranged one above the other or overlapping, i.e., designed as a combination section, where the combination section serves simultaneously as both the active section and the adhesive section. The entire surface of the patch can be designed as such a combination section, or only one or more sections can be configured as combination sections. It is particularly preferred that the patch has a central combination section, with the adhesive section overlapping the combination section, and the patch thus having a border that serves solely as an adhesive section.To achieve particularly good adhesion of the patch at the application site, the adhesive properties in this adhesive section are preferably more pronounced than in the central combination section. Alternatively, the patch can have only a central active section without adhesive properties instead of the combination section. A plaster according to the invention can also have different structures with regard to the layers present. The plaster can comprise one or, preferably, several layers. For example, the plaster can comprise only a single homogeneous layer comprising the adhesive section and the active section in one. Alternatively, the patch can also be constructed in at least two layers, with the layer containing the active section arranged on top of the layer containing the adhesive section, which faces the application site. In this case, the superimposed layers can be aligned or overlapping. In the case of an overlapping arrangement, the layer containing the adhesive section overlaps the layer containing the active section. Furthermore, the patch can have more than two layers, with at least one adhesive section present on the layer facing the application site. The remaining layers can be, for example, layers with active sections and / or other layers, preferably with at least two layers having an active section, thereby enabling a continuous but time-delayed release of the active ingredient from the individual layers. In this case as well, the superimposed layers can be arranged congruently or overlapping. In the case of an overlapping arrangement, the layer containing the adhesive section overlaps the other layers. In the context of the present invention, "topical" means for external, local application, so that the active ingredients - unlike, for example, already known, commercially available pain patches - are not absorbed systemically, but primarily exert their effect only locally. To allow the active ingredient to penetrate the skin particularly quickly and reach the area to be treated, the patch is designed to be at least partially, preferably completely, occlusive in at least one active section and / or at least one adhesive section. This means the patch is at least partially, preferably completely, occlusive. The occlusion of the patch prevents it, or the pharmaceutical preparation it contains, from drying out, which would prevent absorption. Furthermore, it softens the skin of the person being treated and opens the pores, thus improving drug absorption. Using a patch significantly increases patient compliance and ease of application, as the patch simply needs to be applied to the affected area without any further steps.This eliminates the disadvantages of known application methods, such as pain relief gels that need to be applied and rubbed in, because the occlusion of the patch prevents the gel from drying out. The absorption of the active ingredient is thus accelerated, and the duration of use can be reduced. For the treatment of sinusitis, a therapeutically effective amount of a non-steroidal anti-inflammatory drug and / or its physiologically compatible compounds / salts and / or physiologically compatible chemical derivatives is included. Those skilled in the art are familiar with the non-steroidal anti-inflammatory drugs, the compounds / salts or chemical derivatives particularly advantageous for topical application, and the required therapeutically effective amount for topical application, so further details are unnecessary. For example, a therapeutically effective amount of approximately 180 mg, preferably at least 180 mg, of diclofenac diethylamine in a patch could be considered. An application time of at least 30 minutes is particularly advantageous in this context. Preferably, this process is repeated with another patch containing approximately 180 mg, preferably at least 180 mg, of the active ingredient to achieve a particularly good local effect. Alternatively, for example, twice the amount, i.e., approximately 360 mg, preferably at least 360 mg, of the active ingredient could be contained in a single patch, and the release could be controlled over approximately 1 hour, preferably over 1 to 3 hours. Of course, it is not excluded that patches with less, for example 150 mg diclofenac diethylamine, or more active ingredient, for example 200 mg diclofenac diethylamine, may be used. In this case, preferably two patches are applied to the application site 30 minutes apart. Alternatively, patches containing 300 mg or 400 mg diclofenac diethylamine can be used for a duration of approximately 1 hour, preferably 1 to 3 hours, ensuring continuous release of the active ingredient. The amount of active ingredient must, of course, be adjusted to the size of the patch and its permeability, particularly in the aforementioned combination section, to the skin in order to achieve the desired rapid application time.The amount of active ingredient is adapted to the properties of the patch, ensuring in any case that a sufficient amount of active ingredient is released and transported to the site of action. Preferably, the active ingredient is released gradually, i.e., at a release rate that can be considered essentially constant over a certain period of time. This is particularly preferably done over a period of 1 to 3 hours. To ensure comfortable wear and minimize the size of the application site, the patch is designed to conform to the anatomical contours of the application area. This application site is located on the face, specifically in the area of ​​at least one of the sinuses, preferably on the cheek of the patient. This allows for targeted percutaneous treatment of sinusitis. "Anatomically adapted" means that the contour of the corresponding area on the face, particularly in the cheek area, is taken into account. The rectangular shape of pain patches known in the prior art is unsuitable for the face of a person being treated because, among other things, it results in dimensions that are far too large. This causes such a patch to wrinkle, which negatively affects the absorption of the active ingredient. Furthermore, the application area is much too large, which would result in the absorption of an unnecessarily large amount of the active ingredient, potentially leading to undesirable side effects such as stomach upset. These large dimensions are necessary in patches or preparations known in the prior art to ensure sufficient absorption of the active ingredient, thereby achieving a systemic effect. Moreover, the size is required to provide a sufficiently large reservoir of the active ingredient.The limitation to a specific, local area, as with topical applications, is therefore not necessary with such plasters known from the prior art. Furthermore, in the present invention, the shape of the plaster takes into account the facial contours of the person being treated. That is, the shape of the plaster is adapted to the application site to prevent unwanted waviness. This ensures that the plaster adheres well to the application site and is comfortable for the patient. The shape and dimensions of the plaster take the application site into account; that is, the shape is adapted to the area of ​​sinusitis. Therefore, plasters of different shapes can be used. In each case, the shape and size are adapted to the application site to achieve the highest possible level of comfort for the person being treated.For example, a kidney-shaped plaster is particularly advantageous for treating sinusitis in the maxillary sinuses. Of course, round plasters can also be considered. In one embodiment of the present invention, the patch is designed such that the adhesive section is adapted to the sensitive skin at the application site on the face, in the area of ​​at least one of the sinuses, preferably in the area of ​​a cheek, of the person being treated, in order to prevent irritation and / or injury to the sensitive skin. Conventional pain patches containing NSAIDs are intended for use on the body away from the face or head. Accordingly, adhesives with higher adhesion properties can be used to prevent the patches from being lost due to body movements—such as bending the arms / legs or twisting the torso, etc. However, the adhesives used are typically less suitable for the sensitive facial skin, as removing the patch can damage the significantly more sensitive facial skin.The skin could be injured. Therefore, for the sensitive facial skin, the present invention preferably uses particularly suitable adhesives, such as those known from plasters for cosmetic purposes or for the treatment of strabismus in childhood. Alternatively, the adhesive effect of the adhesive section can also be achieved via adhesion and / or a corresponding structure of the adhesive section, as is known from the prior art, particularly from gel pads for cosmetic purposes. In this context, it should also be noted that the plaster according to the invention can be designed in such a way that, due to the relatively small adhesive area, it does not damage the sensitive facial skin. In particular, adhesive sections in the form of so-called wound closure strips ("strips") are suitable for the plasters according to the invention, as they exhibit very good adhesion properties even with narrower adhesive areas, especially with regard to removability. In an alternative embodiment of the invention, the patch is provided to be a matrix patch in order to enable the most targeted release of the active ingredient possible and to control the absorption of the active ingredient through the matrix properties of the patch and through the barrier properties of the skin, while maintaining a compact structure of the patch. In a further embodiment of the invention, the patch is provided to be a membrane patch in order to enable the most targeted release of the active ingredient possible and to control the release of the active ingredient via a control membrane. In one embodiment of the invention, the plaster is essentially kidney-shaped, semicircular, teardrop-shaped, round, oval, trapezoidal, square, U-shaped, C-shaped, triangular, or half-ellipse. These shapes allow for particularly good adaptation to the facial contours of the person being treated. Naturally, the size is also adapted to the anatomical requirements. These shapes also allow the application area to be kept as small as possible. Kidney-shaped plasters are particularly preferred, however, as they adapt especially well to the cheek contours of a person's face. Of course, other shapes are not excluded. In one embodiment, the patch is designed to have a length of approximately 6 cm to 9 cm and a width of approximately 4 cm to 6 cm to ensure a suitable size with a sufficient amount of active ingredient, while simultaneously keeping the area for local application as small as possible to minimize unwanted side effects. Preferably, the patch has a length of approximately 7.5 cm to 8 cm and a width of approximately 4.5 cm to 5 cm. This makes the patch ideally suited for both smaller and larger faces, such as those of women and men. In a further embodiment of the invention, the patch comprises a pharmaceutical preparation, preferably an ointment, cream, or gel, which contains the non-steroidal anti-inflammatory drug (NSAID) to ensure particularly simple manufacturing of the patch. For this embodiment, for example, a conventional patch known in the prior art is combined with an NSAID-containing cream, ointment, or gel. Alternatively, the corresponding ointment, cream, or gel preparation can be combined with the patch in other ways known in the prior art, for example, in the form of a depot. In a further embodiment of the invention, it is provided that the non-steroidal anti-inflammatory drug or active ingredient is selected from the group consisting of salicylic acid derivatives, aryl acetic acid derivatives, indole acetic acid derivatives, aryl proprioceptive acid derivatives, anthranilic acid derivatives, oxicams, pyrazolidinediones and COX-2 inhibitors, in order to provide the patch for the treatment of sinusitis with particularly suitable anti-inflammatory and analgesic properties. In one embodiment of the invention, it is provided that the non-steroidal anti-inflammatory drug or active ingredient is diclofenac, in particular diclofenac diethylamine, in order to ensure a particularly rapid and effective treatment of sinusitis, because diclofenac is particularly effective as an anti-inflammatory and analgesic. Diclofenac diethylamine is particularly suitable for topical application due to its absorption properties. However, diclofenac can also be used as another known physiologically compatible compound / salt and / or physiologically compatible chemical derivative, such as diclofenac sodium. Alternatively, the active ingredient ibuprofen could also be used for a plaster according to the invention. In a further embodiment of the invention, the patch contains at least one additional active ingredient in at least one active section in order to make the treatment of sinusitis even more effective. This additional active ingredient could be another NSAID such as ibuprofen or another advantageous active ingredient. For example, an additional active ingredient could be a decongestant or a warming agent such as capsaicin. In a preferred embodiment of the invention, the patch is provided to contain at least one further decongestant in at least one active ingredient in at least one of its active sections, in order to facilitate the drainage of secretions from the sinuses in addition to the anti-inflammatory effect of the patch. The decongestant reduces the swelling in the sinus passages, thereby clearing them and allowing the secretions to drain away. In a particularly preferred embodiment of the invention, the at least one decongestant is selected from the group consisting of sympathomimetics, glucocorticoids, and decongestant essential oils to achieve a particularly effective decongestant action. Suitable sympathomimetics include, in particular, xylometazoline, oxymetazoline, and tramazoline. Suitable glucocorticoids include, in particular, mometasone, dexamethasone, or beclomethasone. Suitable decongestant essential oils include, in particular, eucalyptus oil, thyme oil, and lavender oil. Physiologically compatible compounds / salts and / or physiologically compatible chemical derivatives of the active ingredients are also suitable. In a particularly preferred embodiment of the invention, it is provided that the at least one decongestant active ingredient is xylometazoline, in particular xylometazoline hydrochloride, in order to achieve a particularly suitable decongestant effect in the plaster. The patch may be designed to contain at least one excipient in at least one active section to improve topical application. This could include, for example, substances that improve absorption or enhance occlusion. Accordingly, in a preferred embodiment of the invention, the patch further contains at least one excipient in at least one active section, wherein the at least one excipient increases the absorption of the at least one active ingredient in order to enable a shorter application time of the patch. The improved absorption results in a faster onset of action at the site of action, thereby shortening the application time. In a particularly preferred embodiment of the invention, at least one excipient is dimethyl sulfoxide (DMSO). DMSO is a well-known carrier molecule that improves the absorption of active ingredients. Furthermore, it is itself anti-inflammatory and analgesic, making it particularly suitable for use in a plaster according to the invention. Of course, it is not out of the question that other excipients that increase absorption may be used. The invention further provides a kit. The kit comprises a patch as described above and a device for the intranasal application of a pharmaceutical preparation in the form of nasal drops or a nasal spray for the treatment of sinusitis. The kit enables particularly effective treatment of sinusitis, whereby the patch is generally applied first, followed by the nasal drops. That is, the person being treated first applies the patch to the desired application site on the face and leaves it in place. The patch should generally remain in place for between 30 minutes and a maximum of 3 hours, or 2 hours 30 minutes, or 2 hours, or 1 hour 30 minutes, or 1 hour. It is particularly preferred that the patch remains in place for 1 hour to 2 hours, and especially preferably for 1 hour 30 minutes.Depending on the duration of use, a delayed-release formulation of the active ingredient may be necessary to prevent a sudden release of the entire dose. Alternatively, the dosage can be adjusted. The pharmaceutical preparation is then administered. This will typically be a commercially available nasal drop or nasal spray, which should be used according to the instructions. According to the invention, the pharmaceutical preparation for intranasal application contains at least one decongestant to promote the drainage of nasal secretions from the sinuses. In this context, all decongestants known in the prior art that can be administered intranasally are suitable. For example, it is just as possible to use a saline nasal spray or a herbal preparation as a combination with an active drug or medical device. In a preferred embodiment of the invention, the decongestant active ingredient of the pharmaceutical preparation for intranasal administration is selected from the group of sympathomimetics, the group of glucocorticoids, and / or the group of decongestant essential oils to particularly promote the drainage of nasal secretions from the sinuses. Typically, pharmaceutical preparations for intranasal administration comprising xylometazoline, oxymetazoline, or tramazoline from the sympathomimetic class, mometasone, dexamethasone, or beclomethasone from the glucocorticoid class, and eucalyptus oil, thyme oil, and lavender oil from the essential oil class are used. Of course, a combination with other substances and active ingredients is not excluded. Physiologically compatible compounds / salts and / or physiologically compatible chemical derivatives of the active ingredients are also suitable. Analogous to the above, in the case of diclofenac for use in a method for the topical treatment of sinusitis, it is provided according to the invention that a plaster according to the invention is used for treatment. Furthermore, in a preferred embodiment of diclofenac according to the invention for use in a method for the topical treatment of sinusitis, the active ingredient is diclofenac diethylamine and is contained in a therapeutically effective amount of 180 mg, preferably at least 180 mg. In a particularly preferred embodiment of diclofenac according to the invention for use in a method for the topical treatment of sinusitis, it is provided that the therapeutically effective amount is controlled over a period of at least 30 minutes. BRIEF DESCRIPTION OF THE FIGURES The invention will now be explained in more detail using an exemplary embodiment. The drawing is exemplary and is intended to illustrate the inventive concept, but in no way to restrict or even exhaustively represent it. Figure 1 shows a plaster according to the invention applied to the application site on the face of a person to be treated. WAYS TO IMPLEMENT THE INVENTION Fig. 1 shows an embodiment of the plaster 1 according to the invention. The plaster 1 is designed as a matrix plaster for the topical treatment of sinusitis in a person to be treated. The patch 1 comprises an active section 2 and an adhesive section 3, the adhesive section 3 being larger than or surrounding the active section 2. The adhesive section 3 of the patch 1 is essentially semicircular, essentially half-ellipse in shape, or essentially a U-shaped shape with a top end, also known as a "long U" or "U with a macron," written as "Ū," and found, for example, in the Latvian alphabet. In a central area of ​​the patch 1, the adhesive section 3 serves simultaneously as both the adhesive section 3 and the active section 2; that is, the two sections are congruent or overlapping in this area of ​​the patch 1. This combined section 4 of the active section 2 and the adhesive section 3 is positioned centrally on the patch 1 such that the combined section 4 is bordered by the protruding adhesive section 3.The portion of the adhesive section 3 that extends beyond the combination section 4 ensures particularly good adhesion of the patch 1 to the application site. It should be noted that, preferably, the adhesive properties of the adhesive section 3 are less pronounced in the combination section 4, i.e., the adhesion is lower than in the adhesive section 3 that extends beyond or does not overlap the combination section 4. The paving 1 has a length L in the range of 7.5 cm to 8 cm and a width B in the range of 4.5 cm to 5 cm, see Fig. 1 . The patch 1 contains, in its active section 2, at least one active ingredient: a therapeutically effective amount of a non-steroidal anti-inflammatory drug and / or its physiologically compatible compounds / salts and / or physiologically compatible chemical derivatives. In the present embodiment, the active section 2 contains diclofenac diethylamine. Furthermore, dimethyl sulfoxide (DMSO) is included as a carrier substance or as an absorption enhancer. Patch 1, with its essentially semicircular shape, is adapted to the anatomical features of the application site. This site is located on the face, in the area of ​​at least one of the paranasal sinuses, on the cheek of the person being treated, to enable targeted percutaneous treatment of sinusitis. This allows Patch 1 to conform particularly well to the contours of the face in the cheek area. Consequently, premature detachment and wrinkling of Patch 1 are prevented, thus increasing the patient's comfort. Not shown in Fig. 1 is that the patch 1 can be part of a kit which further includes an intranasally applicable pharmaceutical preparation in the form of a nasal spray. In the present embodiment, the nasal spray contains xylometazoline hydrochloride as the active ingredient. REFERENCE MARK LIST 1 Patch 2 Active section 3 Adhesive section 4 Combination section L Length of patch B Width of patch QUOTES INCLUDED IN THE DESCRIPTION This list of documents cited by the applicant was automatically generated and is included solely for the reader's convenience. The list is not part of the German patent or utility model application. The DPMA accepts no liability for any errors or omissions. Cited patent literature WO 2023 / 154479 A1

[0006] WO 20220531 28 A

[0007]

Claims

Patch (1) for the topical treatment of sinusitis in a person to be treated, the patch comprising at least one active section (2) with at least one active ingredient and at least one adhesive section (3), wherein the patch (1) is at least partially, preferably completely, occlusive in the at least one active section (2) and / or in the at least one adhesive section (3), characterized in that the at least one active section (2) contains a therapeutically effective amount of a non-steroidal anti-inflammatory drug and / or its physiologically acceptable compounds / salts and / or physiologically acceptable chemical derivatives as the at least one active ingredient, and that the patch (1) has a shape adapted to the anatomical features of the application site, wherein the application site is located on the face in the area of ​​at least one of the paranasal sinuses, preferably in the area of ​​a cheek, of the person to be treated.to enable targeted percutaneous treatment of sinusitis. Plaster (1) according to claim 1 , characterized in that the non-steroidal anti-inflammatory drug is selected from the group consisting of: salicylic acid derivatives, arylacetic acid derivatives, indoleacetic acid derivatives, arylpropionic acid derivatives, anthranilic acid derivatives, oxicams, pyrazolidinediones and COX-2 inhibitors. Plaster (1) according to one of the preceding claims, characterized in that the plaster (1) is essentially kidney-shaped, semicircular, teardrop-shaped, round, oval, trapezoidal, square, U-shaped, C-shaped, triangular or as a half ellipse. Paving stone (1) according to one of the preceding claims, characterized in that the paving stone (1) has a length of between 6 cm and 9 cm and a width of between 4 cm and 6 cm. Patch (1) according to one of the preceding claims, characterized in that the patch (1) comprises a pharmaceutical preparation, preferably an ointment, a cream or a gel, which pharmaceutical preparation contains the non-steroidal anti-inflammatory drug. Plaster (1) according to one of the preceding claims, characterized in that the non-steroidal anti-inflammatory drug is diclofenac, in particular diclofenac diethylamine, or ibuprofen. Patch (1) according to one of the preceding claims, characterized in that the patch (1) contains at least one further active ingredient in at least one active section, wherein preferably the patch (1) further contains at least one decongestant active ingredient in at least one active section (2) as the at least one further active ingredient, wherein the at least one decongestant active ingredient is particularly preferably selected from the group consisting of sympathomimetics, glucocorticoids, decongestant essential oils. Plaster (1) according to claim 7, characterized in that the at least one decongestant active ingredient is xylometazoline, in particular xylometazoline hydrochloride. Patch (1) according to one of the preceding claims, characterized in that the patch (1) further contains at least one excipient in at least one active section, wherein the at least one excipient increases the absorption of the at least one active ingredient, wherein the at least one excipient is preferably dimethyl sulfoxide (DMSO). Kit comprising a patch (1) according to one of claims 1 to 9 and a device for intranasal application of a pharmaceutical preparation in the form of nasal drops or a nasal spray for the treatment of sinusitis, wherein the pharmaceutical preparation for intranasal application contains at least one decongestant active ingredient, wherein preferably the decongestant active ingredient of the pharmaceutical preparation for intranasal administration is selected from the group of sympathomimetics, the group of glucocorticoids and / or the group of decongestant essential oils.

Images